{'52WeekChange': -0.08111614,
 'SandP52WeekChange': None,
 'address1': 'The Omeros Building',
 'address2': '201 Elliott Avenue West',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.91,
 'askSize': 1000,
 'averageDailyVolume10Day': 234712,
 'averageVolume': 408096,
 'averageVolume10days': 234712,
 'beta': 1.844257,
 'beta3Year': None,
 'bid': 13.9,
 'bidSize': 1000,
 'bookValue': -2.419,
 'category': None,
 'circulatingSupply': None,
 'city': 'Seattle',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 14.385,
 'dayLow': 13.77,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -13.627,
 'enterpriseToRevenue': 7.92,
 'enterpriseValue': 899457280,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '206 676 5005',
 'fiftyDayAverage': 14.684571,
 'fiftyTwoWeekHigh': 20.92,
 'fiftyTwoWeekLow': 8.5,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 44042439,
 'forwardEps': -1.95,
 'forwardPE': -7.128205,
 'fromCurrency': None,
 'fullTimeEmployees': 258,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.05392,
 'heldPercentInstitutions': 0.54514,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/omeros.com',
 'longBusinessSummary': 'Omeros Corporation, a biopharmaceutical company, '
                        'discovers, develops, and commercializes '
                        'small-molecule and protein therapeutics, and orphan '
                        'indications targeting inflammation, '
                        'complement-mediated diseases, disorders of the '
                        'central nervous system (CNS), and immune-related '
                        'diseases. It provides OMIDRIA for use in cataract '
                        'surgery or intraocular lens replacement in the United '
                        "States. The company's clinical programs include "
                        'Narsoplimab (OMS721/MASP-2) that is in Phase III '
                        'clinical trial for hematopoietic stem-cell '
                        'transplant-associated thrombotic microangiopath, '
                        'immunoglobulin A nephropathy, and atypical hemolytic '
                        'uremic syndrome; and Phase II clinical trial to treat '
                        'lupus nephritis and other renal diseases. Its '
                        'clinical programs also consists of PPAR? (OMS405) '
                        'that is in Phase II clinical trial to treat opioid '
                        'and nicotine addiction; and PDE7 (OMS527), which is '
                        'in Phase I clinical trial for treating addiction and '
                        'compulsive disorders, and movement disorders. In '
                        "addition, the company's preclinical programs comprise "
                        'MASP-3 (OMS906) for paroxysmal nocturnal '
                        'hemoglobinuria (PNH) and other alternative pathway '
                        'disorders; MASP-2-small-molecule inhibitors used for '
                        'the treatment of aHUS, IgAN, HSCT-TMA, and '
                        'age-related macular degeneration; and '
                        'MASP-3-small-molecule inhibitors to treat PNH and '
                        'other alternative pathway disorders. Further, its '
                        'preclinical programs include G protein-coupled '
                        'receptor (GPCR) platform, including GPR174, GPR151, '
                        'GPR161, and other Class A orphan GPCRs for treating '
                        'immunologic, immuno-oncologic, metabolic, CNS, '
                        'cardiovascular (CV), musculoskeletal, and other '
                        'disorders; and antibody platform for metabolic, CV, '
                        'oncologic, musculoskeletal, and other disorders. The '
                        'company was incorporated in 1994 and is headquartered '
                        'in Seattle, Washington.',
 'longName': 'Omeros Corporation',
 'market': 'us_market',
 'marketCap': 757698688,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_32388',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -89172000,
 'nextFiscalYearEnd': 1640908800,
 'open': 14.16,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.08,
 'phone': '206 676 5000',
 'previousClose': 14.16,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 6.6720557,
 'profitMargins': -0.78522,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 14.385,
 'regularMarketDayLow': 13.77,
 'regularMarketOpen': 14.16,
 'regularMarketPreviousClose': 14.16,
 'regularMarketPrice': 14.16,
 'regularMarketVolume': 172583,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 54510700,
 'sharesPercentSharesOut': 0.20030001,
 'sharesShort': 10919810,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 10935532,
 'shortName': 'Omeros Corporation',
 'shortPercentOfFloat': 0.21079999,
 'shortRatio': 25.56,
 'startDate': None,
 'state': 'WA',
 'strikePrice': None,
 'symbol': 'OMER',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.754,
 'twoHundredDayAverage': 14.15259,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '3f7c487e-99e5-35b0-97bc-8da48930057f',
 'volume': 172583,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.omeros.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '98119'}